Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 11/20 | 1.00 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.81 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1170110 | 0.98 | TLR8 (1.00) | TLR8CXCR4POLBCYP1A2CYP2D6 | |
| SCHEMBL2343059 | 0.94 | TLR8 (1.00) | TLR8CXCR4POLBCYP1A2CYP2D6 | |
| SCHEMBL14447553 | 0.92 | CXCR4 (0.96) | TLR8CXCR4POLBCYP1A2CYP2D6 | |
| SCHEMBL6197634 | 0.92 | CXCR4 (0.96) | TLR8CXCR4POLBCYP1A2CYP2D6 | |
| SCHEMBL6196399 | 0.90 | CXCR4 (1.00) | TLR8CXCR4POLBCYP1A2CYP2D6 | |
| SCHEMBL1520381 | 0.87 | POLB (1.00) | TLR8CXCR4POLBCYP1A2CYP2D6 | |
| SCHEMBL7164854 | 0.87 | CXCR4 (0.93) | TLR8CXCR4POLBCYP1A2CYP2D6 | |
| SCHEMBL22844179 | 0.84 | CXCR4 (0.81) | TLR8CXCR4POLBCYP1A2CYP2D6 | |
| SCHEMBL22844258 | 0.84 | CXCR4 (0.81) | TLR8CXCR4POLBCYP1A2CYP2D6 | |
| SCHEMBL30814682 | 0.84 | CXCR4 (0.81) | TLR8CXCR4POLBCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10471139-B2 | Toll-like receptor agonists | THE UNIVERSITY OF KANSAS (US) | 2019-11-12 | — | — | US | disclosed |
| US-20160166681-A1 | TOLL-LIKE RECEPTOR AGONISTS | THE UNIVERSITY OF KANSAS | 2016-06-16 | — | — | US | disclosed |
| US-20160166681-A1 | TOLL-LIKE RECEPTOR AGONISTS | THE UNIVERSITY OF KANSAS | 2016-06-16 | — | — | US | disclosed |
| WO-2015023958-A1 | TOLL-LIKE RECEPTOR AGONISTS | THE UNIVERSITY OF KANSAS (US) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166681-A1 | TOLL-LIKE RECEPTOR AGONISTS | TLR1, TLR7, TLR8 | TLR8 3/4885CXCR4 300/4885POLB 1271/4885 |
| US-10471139-B2 | Toll-like receptor agonists | TLR1, TLR7, TLR8 | TLR8 3/4885CXCR4 300/4885POLB 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.